National Institute for Health Research

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

Retrieved on: 
Thursday, January 19, 2023
Research, General Health, Pharmaceutical, Philanthropy, Oncology, Hospitals, Genetics, Foundation, Clinical Trials, Science, Biotechnology, Health, Royal Marsden Hospital, United Kingdom, Circulating tumor DNA, CRC, MRD, National Institute for Health Research, Part, Colorectal cancer, MRC, Public, NIHR, DNA, Efficacy, Risk, Medical Research Council, Partnership, Neurotoxicity, Patient, Helmy Eltoukhy, Trust, Cancer, NHS foundation trust, The Royal Marsden NHS Foundation Trust, III, Neoplasm, EME, GH, Pharmaceutical industry, Medical imaging

The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the Guardant Reveal™ blood test following surgery.

Key Points: 
  • The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the Guardant Reveal™ blood test following surgery.
  • The study will use the Guardant Reveal blood test to detect MRD by measuring the DNA shed from tumor cells into the bloodstream.
  • “Patients with high-risk colorectal cancer are often over-treated and can suffer long-term neurotoxicity from chemotherapy,” said Professor David Cunningham, director of clinical research at The Royal Marsden NHS Foundation Trust, chief investigator for the TRACC Part C study.
  • The Royal Marsden NHS Foundation Trust announced that the first patient was enrolled in TRACC Part C in September 2022.

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Retrieved on: 
Friday, October 7, 2022
COVID-19, Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, MSD, UKRI, NHS, National Institute, Antipyretic, HR, UK Research and Innovation, Omicron, Disease, Hospital, National Institute for Health Research, Medicine, Fatigue, Risk, MHRA, Merck & Co., Population, Early, Policy, Severe acute respiratory syndrome coronavirus 2, COVID, Immunity, Particle-size distribution, NYSE, Patient, Mortality, Community, NIHR, University, COVID-19, Virology, Novel, Research, Safety, BCI, CI, Death, MRK, Trial of the century, Comorbidity, Cough, Pharmaceutical industry, Health insurance, Merck, Clalit Health Services

Additionally, Merck is reporting results from a recent carcinogenicity study in transgenic mice, which demonstrated that LAGEVRIO was not carcinogenic at any dose tested.

Key Points: 
  • Additionally, Merck is reporting results from a recent carcinogenicity study in transgenic mice, which demonstrated that LAGEVRIO was not carcinogenic at any dose tested.
  • Of them, 19,868 patients were eligible for LAGEVRIO therapy; 1,069 (5%) patients received at least one dose of LAGEVRIO.
  • Global access has been a priority for Merck and Ridgeback since the inception of their LAGEVRIO collaboration.
  • Since licensed by Ridgeback, all funds used for the development of LAGEVRIO have been provided by Merck and Ridgeback.

CMS Assigns New Technology Payment Classification for Optellum's Lung Cancer Prediction Score

Retrieved on: 
Tuesday, June 28, 2022
Diagnosis, Patient, One Oxford Centre, National Institute, Health, SEER, LCP, Interstitial lung disease, AAC, Degenerative disease, Department, FDA, Centers for Medicare & Medicaid Services, Lung cancer, Texas Medical Center, Radiology, MD Anderson Cancer Center, CT, Medical University of South Carolina, Investment, Academic health science centre, BS, Medical school, NLST, National Lung Screening Trial, Twitter, III, LinkedIn, ILD, COPD, Center, National Institute for Health Research, NIHR, NHS, Certification, Technology, Survival rate, AI, Multimedia, Hospital, MedCity, CMS, Disease, Professor, CE, CPT, UKCA, Medicine, Physician, Chronic obstructive pulmonary disease, Medical imaging, Medical device, Epidemiology, Medicare

HOUSTON and OXFORD, United Kingdom, June 28, 2022  /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification. This development will facilitate the process of health insurance claims for individuals enrolled in Medicare and other health insurance programs, enabling more patients to access innovative, potentially life-saving early lung cancer diagnostic technology.

Key Points: 
  • HOUSTON and OXFORD, United Kingdom, June 28, 2022 /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification.
  • "This is another step in Optellum's progress towards becoming the standard of care for early lung cancer diagnosis.
  • "This new payment assignment is an important step towards incentivizing providers to make the technology more widely available."
  • He has extensive experience in the application and translation of imaging research for evaluating lung nodules and lung cancer.

Outlook on the Telecare Global Market to 2027 - Increasing Geriatric Population All Over the World is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 19, 2022
Technology, General Health, Health, Telecommunications, Employment, Consciousness, Population, Ageing, Falls, World, Hospital, National Institute, Environment, Patient, World Health Organization, Walking, Disability, National Institute for Health Research, Government, Solution, Paralysis, Legislation, Telehealth, Industry, Telecare, Technology, Safety, Adoption, CAGR, Growth, Lists of countries and territories, Renewable energy, Healthcare, Health insurance

The Global Telecare Market size is expected to reach $5.5 billion by 2027, rising at a market growth of 5.7% CAGR during the forecast period.

Key Points: 
  • The Global Telecare Market size is expected to reach $5.5 billion by 2027, rising at a market growth of 5.7% CAGR during the forecast period.
  • Telecare is a dynamic technology that delivers healthcare services to patients across remote regions digitally as well as virtually.
  • Moreover, the increasing geriatric population around the world is expected to fuel the telecare industry in the upcoming years.
  • According to the World Health Organization, one in every six individuals in the world will be over 60 years old by 2030.

NexCore Group Hires Carolyn Wilson as Strategy and Planning Advisor

Retrieved on: 
Wednesday, May 11, 2022
M Health Fairview, Registered nurse, University, Business administration, Benedictine University, Rush University, University of Chicago Medical Center, National Institute, Modern Healthcare, M Health Fairview University of Minnesota Medical Center, Ingalls Memorial Hospital, Chicago (franchise), Hospital, HRE, Marketing, Bachelor of Science in Nursing, National Institute for Health Research, Beaumont Health, Healthcare Facilities Accreditation Program, Partner (business rank), Ambulatory care, Medicine, Management, Science, Nursing

DENVER, May 11, 2022 /PRNewswire-PRWeb/ -- Denver-based NexCore Group, a national healthcare real estate (HRE) developer, today announced Carolyn Wilson, a 30-year veteran of the healthcare industry, has joined NexCore Group as a Strategy and Planning Advisor.

Key Points: 
  • DENVER, May 11, 2022 /PRNewswire-PRWeb/ -- Denver-based NexCore Group, a national healthcare real estate (HRE) developer , today announced Carolyn Wilson, a 30-year veteran of the healthcare industry, has joined NexCore Group as a Strategy and Planning Advisor.
  • "Carolyn is further proof of NexCore's commitment to differentiation through strategy and planning added value services.
  • While at Beaumont, Ms. Wilson collaborated with NexCore on the development of two 100,000+ square foot comprehensive outpatient campuses, exceeding business expansion objectives.
  • NexCore is unique in the healthcare development field, specifically with a regard to a singular focus on project strategy and planning.

Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference

Retrieved on: 
Tuesday, April 5, 2022
Company, Virus, WHO, Intubation, Death, Multimedia, Patient, NIHR, Delta, National Institute, SPRINTER, University of Southampton, Food, Interferon, OSCI, Safety, US Foods, COVID-19, LSE, Drug discovery, Cox, Inhalation, FDA, Synairgen, University, National Institute for Health Research, Disease, AIM, Pharmaceutical industry, Birth control, Omicron

Patients requiring high-flow nasal oxygen therapy, non-invasive ventilation, or endotracheal intubation (invasive ventilation) at randomisation were excluded.

Key Points: 
  • Patients requiring high-flow nasal oxygen therapy, non-invasive ventilation, or endotracheal intubation (invasive ventilation) at randomisation were excluded.
  • COVID-19 was confirmed using a validated molecular test for the presence of the SARS-CoV-2 virus.
  • The topline data from Synairgen's Phase 3 clinical programme evaluating SNG001 in patients across 17 countries was announced in February 2022 and detailed analysis of the data is ongoing.
  • Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG).

ZS and IgniteData Partner to Transform Patient Data Automation for Clinical Trials

Retrieved on: 
Tuesday, February 1, 2022
Software, Research, Professional Services, Pharmaceutical, Data Management, Technology, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, Health, Consulting, CEO, University College Hospital, National Institute for Health Research, Patient, Automation, EDC, UCLH, API, ZS, EHR, Twitter, University College London Hospitals NHS Foundation Trust, Technology, Efficiency, Research, UCL, Partnership, Biomedical Research, Cerner, Health, Life, UCLH/UCL Biomedical Research Centre, Time, LinkedIn, NIHR, Health information management, National Institute, Solution, Hospital, Pharmaceutical industry, Medical imaging, Central London, Archery, ZS, IgniteData, UCLH, ZS, IGNITEDATA, UCLH

The goal for this partnership is to improve the efficiency of clinical research through automation and use of real-world data, which will ultimately expedite pharmaceutical product and therapy innovation and improve patient outcomes.

Key Points: 
  • The goal for this partnership is to improve the efficiency of clinical research through automation and use of real-world data, which will ultimately expedite pharmaceutical product and therapy innovation and improve patient outcomes.
  • The partnership will enhance interoperability between electronic health records (EHR) and core research applications such as electronic data capture (EDC) systems to improve the efficiency of patient data collection for research institutions and sponsors within the context of clinical research.
  • ZSs vision is to transform what tomorrows research ecosystem looks like, stated Pratap Khedkar, CEO of ZS.
  • A key area of work is digital healthcare and enabling data-enabled trials in order to improve health through data.

Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, January 25, 2022
Nasdaq, Adult, Vaccine, COVID-19, 1018, Vaccination, National Institute for Health Research, Saint-Herblain, Lyme disease, Technology, Delta, Severe acute respiratory syndrome coronavirus 2, Chikungunya, AZD1222, National Institute, Company, CpG, Ageing, NIHR, Infection, EMA, Omicron, Vero, VLA2001

Saint-Herblain (France), January 25, 2022 Valneva SE , a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare.

Key Points: 
  • Saint-Herblain (France), January 25, 2022 Valneva SE , a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare.
  • This booster extension is intended to provide both homologous and first heterologous booster data to complement previous positive Phase 1/2 booster results.
  • The VLA2001 booster vaccination will be given at least seven months after completion of the primary vaccination series.
  • In addition, Valneva plans to initiate a further dedicated heterologous booster only trial of VLA2001 in the coming weeks.

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Retrieved on: 
Tuesday, January 25, 2022
National Institute for Health Research, Patient, Research, Technology, TRE, News, UCLH/UCL Biomedical Research Centre, BRC, Cambridge University Health Partners, Genomics England, Tres, Data management, Cambridge Biomedical Campus, Department of Health and Social Care, Disease, Organic, Government, Department, Health, National Institute, NHS, Public health, Secretary of State for International Development, Industry, DARE, Multimedia, Cancer, Biomedical Research, Social work, NIHR, Conditional sentence, Partnership, University, Medical device, Health insurance

As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.

Key Points: 
  • As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.
  • The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research.
  • Based within the most outstanding NHS and University partnerships in the country, the Biomedical Research Centres are leaders in scientific translation.
  • Located on the Cambridge Biomedical Campus, they receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new treatments.

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Retrieved on: 
Tuesday, January 25, 2022
National Institute for Health Research, Patient, Research, Technology, TRE, News, UCLH/UCL Biomedical Research Centre, BRC, Cambridge University Health Partners, Genomics England, Tres, Data management, Cambridge Biomedical Campus, Department of Health and Social Care, Disease, Organic, Government, Department, Health, National Institute, NHS, Public health, Secretary of State for International Development, Industry, DARE, Cancer, Biomedical Research, Social work, NIHR, Conditional sentence, Partnership, University, Medical device, Health insurance

As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.

Key Points: 
  • As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.
  • The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research.
  • Based within the most outstanding NHS and University partnerships in the country, the Biomedical Research Centres are leaders in scientific translation.
  • Located on the Cambridge Biomedical Campus, they receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new treatments.